SubsidieMeesterscanceR agnOstic immUnoTherapy predIctioN blood-tEst
PamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment.
Projectdetails
Introduction
Cancer is the second leading cause of death worldwide, accounting for 10 million deaths in 2020. Although 7 Immune Checkpoint Inhibitors (ICI) are approved for different cancer indications and have represented a true breakthrough, only 10-50% of advanced cancer patients respond to the treatment.
Challenges in ICI Treatment
This unpredictability of results, together with 15-60% severe toxicity rates and high prices, are restricting the impact potential of ICIs. Predicting ICI response is critical for fully realizing their potential in treating early-stage tumors and enhancing ICI treatment regimens.
PamGene’s IOpener
PamGene’s IOpener is a ground-breaking in vitro diagnostics testing platform for ICI response prediction. Made possible by PamGene’s proprietary microarray-based kinase activity profiling of host immune cells, it can predict a patient’s response before ICI therapy is started from a simple blood draw.
Vision for Precision Medicine
The IOpener aims to revolutionize the precision-medicine sector, enabling the widespread use of ICIs at any cancer stage.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.669.631 |
Tijdlijn
| Startdatum | 1-8-2023 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PAMGENE INTERNATIONAL BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments. | EIC Accelerator | € 2.500.000 | 2022 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1
The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The development of a predictive biomarker for immunotherapy outcome based on flow cytometry testThe project aims to develop a flow cytometry-based predictive biomarker for immunotherapy response, enhancing personalized treatment and aiding pharmaceutical R&D through the detection of immunotherapy-responsiveness cells (IRCs). | ERC Proof of... | € 150.000 | 2022 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
Precision Diagnostics for Predicting Therapy Response to Bispecific AntibodiesThis project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia. | ERC Proof of... | € 150.000 | 2025 | Details |
Immunogenic cell death (ICD) in the cancer-immune dialogueThis project aims to enhance anticancer treatments by studying immunogenic cell death (ICD) mechanisms and developing strategies to improve tumor immunosurveillance through dendritic cell activation. | ERC Advanced... | € 2.500.000 | 2023 | Details |
EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapyEXPAND IT aims to uncover the mechanisms of T-cell and B-cell expansion in the tumor microenvironment during cancer immunotherapy to enhance patient responses and develop new therapies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
The development of a predictive biomarker for immunotherapy outcome based on flow cytometry test
The project aims to develop a flow cytometry-based predictive biomarker for immunotherapy response, enhancing personalized treatment and aiding pharmaceutical R&D through the detection of immunotherapy-responsiveness cells (IRCs).
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Precision Diagnostics for Predicting Therapy Response to Bispecific Antibodies
This project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia.
Immunogenic cell death (ICD) in the cancer-immune dialogue
This project aims to enhance anticancer treatments by studying immunogenic cell death (ICD) mechanisms and developing strategies to improve tumor immunosurveillance through dendritic cell activation.
EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapy
EXPAND IT aims to uncover the mechanisms of T-cell and B-cell expansion in the tumor microenvironment during cancer immunotherapy to enhance patient responses and develop new therapies.